Agios to Present Clinical Data from Ongoing AG-120 Phase 1 Trial in Advanced Solid Tumors

Agios Pharmaceuticals (NASDAQ:AGIO) will present the first results from the Phase 1 study of AG-120 in patients with IDH1-mutant positive advanced solid tumors in an oral presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place November 5-9, 2015, in Boston.

"We look forward to sharing the first clinical data for AG-120 in patients with advanced solid tumors as we continue to understand the potential of this investigational medicine," said Chris Bowden M.D., chief medical officer at Agios. "This is an important step toward our long-term vision of making a difference for people with a broad range of hematologic and solid tumor cancers that harbor IDH mutations."

The date has been added to the Binary Event Logger calendar.
Go ahead and add it to your .